NCT05164614View on ClinicalTrials.gov

Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 21, 2022

Primary Completion Date

October 10, 2022

Study Completion Date

October 17, 2022

Conditions
Healthy Volunteers
Interventions
COMBINATION_PRODUCT

RT-102 (80 μg)

RaniPill capsule containing PTH with doses of 20 and 80 μg

DRUG

Forteo

A commercial formulation of PTH for SC control (20 µg)

COMBINATION_PRODUCT

RT-102 (20 μg)

RaniPill capsule containing PTH with dose of 20μg

Trial Locations (1)

Unknown

Nucleus Network, Melbourne

Sponsors

Lead Sponsor

RANI Therapeutics
All Listed Sponsors
lead

RANI Therapeutics

INDUSTRY